SANDOZ GROUP AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.26 CHF | -0.89% |
|
+4.06% | +19.22% |
| May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
| May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +19.22% | 15.43B | - | ||
| +21.09% | 43.27B | B- | ||
| +25.28% | 22.92B | B+ | ||
| +13.51% | 12.95B | B+ | ||
| +44.01% | 11.83B | B | ||
| -7.79% | 6.91B | B+ | ||
| -0.05% | 6.79B | - | - | |
| -8.87% | 5.73B | - | - | |
| +13.02% | 5.55B | B+ | ||
| +9.14% | 4.9B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SDZ Stock
- Ratings Sandoz Group AG